×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:NVCN

Neovasc (NVCN) Stock Forecast, Price & News

$5.78
+0.24 (+4.33%)
(As of 05/27/2022 03:58 PM ET)
Add
Compare
Today's Range
$5.38
$5.85
50-Day Range
$5.03
$160.50
52-Week Range
$4.64
$28.25
Volume
35,148 shs
Average Volume
16,294 shs
Market Capitalization
$15.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.48
30 days | 90 days | 365 days | Advanced Chart
Receive NVCN News and Ratings via Email

Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter.

Neovasc logo

About Neovasc

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCN
Employees
49
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.55 million
Book Value
$16.17 per share

Profitability

Net Income
$-24.89 million
Net Margins
-1,192.20%
Pretax Margin
-1,211.86%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$15.65 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/10/2022
Today
5/27/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

863rd out of 1,424 stocks

Surgical & Medical Instruments Industry

91st out of 137 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Neovasc (NASDAQ:NVCN) Frequently Asked Questions

Is Neovasc a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neovasc in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Neovasc stock.
View analyst ratings for Neovasc
or view top-rated stocks.

Are investors shorting Neovasc?

Neovasc saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 5,300 shares, a decline of 76.8% from the April 30th total of 22,800 shares. Based on an average trading volume of 13,500 shares, the short-interest ratio is presently 0.4 days.
View Neovasc's Short Interest
.

When is Neovasc's next earnings date?

Neovasc is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Neovasc
.

How were Neovasc's earnings last quarter?

Neovasc Inc. (NASDAQ:NVCN) posted its quarterly earnings data on Thursday, March, 10th. The medical equipment provider reported ($2.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.50) by $0.25. The medical equipment provider earned $0.76 million during the quarter, compared to the consensus estimate of $0.80 million. Neovasc had a negative trailing twelve-month return on equity of 50.69% and a negative net margin of 1,192.20%.
View Neovasc's earnings history
.

When did Neovasc's stock split? How did Neovasc's stock split work?

Shares of Neovasc reverse split on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of Neovasc stock prior to the reverse split would have 4 shares after the split.

What price target have analysts set for NVCN?

1 Wall Street analysts have issued 12-month target prices for Neovasc's stock. Their forecasts range from $125.00 to $125.00. On average, they anticipate Neovasc's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 2,062.6% from the stock's current price.
View analysts' price targets for Neovasc
or view top-rated stocks among Wall Street analysts.

Who are Neovasc's key executives?
Neovasc's management team includes the following people:
  • Mr. Fredericus A. Colen, Pres, CEO & Director (Age 70, Pay $2.59M)
  • Mr. Christopher Clark B.A., BA (Honours), C.A., CA, PgD, CFO & Corp. Sec. (Age 50, Pay $1.13M)
  • Mr. William Reed Little, Chief Operating Officer (Age 50, Pay $1.2M)
  • Mr. John Christopher Panton, Chief Quality Officer (Age 55, Pay $401.67k)
  • Sarah Marie-Hodgson Gallagher, VP of Clinical Affairs
What other stocks do shareholders of Neovasc own?
What is Neovasc's stock symbol?

Neovasc trades on the NASDAQ under the ticker symbol "NVCN."

How do I buy shares of Neovasc?

Shares of NVCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neovasc's stock price today?

One share of NVCN stock can currently be purchased for approximately $5.78.

How much money does Neovasc make?

Neovasc has a market capitalization of $15.65 million and generates $2.55 million in revenue each year. The medical equipment provider earns $-24.89 million in net income (profit) each year or ($12.00) on an earnings per share basis.

How many employees does Neovasc have?

Neovasc employs 49 workers across the globe.

What is Neovasc's official website?

The official website for Neovasc is www.neovasc.com.

How can I contact Neovasc?

Neovasc's mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider can be reached via phone at (604) 270-4344, via email at [email protected], or via fax at 604-270-4384.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.